Challenges and opportunities in tuberculosis drug discovery: an industry perspective.

Future Medicinal ChemistryVol. 5, No. 5 EditorialChallenges and opportunities in tuberculosis drug discovery: an industry perspectivePravin S Shirude, Sreekanth Ramachandran & Vinayak HosagraharaPravin S Shirude* Author for correspondenceAstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India. Search for more papers by this authorEmail the corresponding author at pravin.shirude@astrazeneca.com, Sreekanth RamachandranAstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, IndiaSearch for more papers by this author & Vinayak HosagraharaAstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, IndiaSearch for more papers by this authorPublished Online:10 Apr 2013https://doi.org/10.4155/fmc.13.26AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: alternative approachcell-based approachtarget-based approachTB drug discoveryReferences1 World Health Organization. Global tuberculosis control report. WHO Press, Geneva, Switzerland (2011).Google Scholar2 Dye C, Williams BG. The population dynamics and control of tuberculosis. Science328,856–861 (2010).Crossref, Medline, CAS, Google Scholar3 Zulma A, Hafner R, Leinhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov.11,171–172 (2012).Crossref, Medline, Google Scholar4 Ginsberg A. The TB alliance: overcoming challenges to chart the future course of TB drug development. Future Med. Chem.3,1247–1252 (2011).Link, CAS, Google Scholar5 Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science307,223–227 (2005).Crossref, Medline, CAS, Google Scholar6 Gravestock MB, Acton DG, Betts MJ et al. New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett.13,4179–4186 (2003).Crossref, Medline, CAS, Google Scholar7 Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev.24,71–109 (2011).Crossref, Medline, CAS, Google Scholar8 Simmons KJ, Chopra I, Fishwick CWG. Structure based discovery of antibacterial drugs. Nat. Rev. Microbiol.8,501–510 (2010).Crossref, Medline, CAS, Google Scholar9 Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature393,537–544 (1998).Crossref, Medline, CAS, Google Scholar10 Shirude PS, Paul B, Choudhury NR, Kedari C, Bandodkar B, Ugarkar B. Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med. Chem. Lett.3,736–740 (2012).Crossref, Medline, CAS, Google Scholar11 Shirude PS, Madhavapeddi P, Tucker JA et al. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and non-replicating Mycobacterium tuberculosis. ACS Chem. Biol.8(3),519–523 (2013).Crossref, Medline, CAS, Google Scholar12 Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov.6,29–40 (2007).Crossref, Medline, CAS, Google Scholar13 Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm. Med.24,151–159 (2010).Crossref, Google Scholar14 Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov. Today Ther. Strateg.8,85–88 (2011).Crossref, Google Scholar15 Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis. J. Antimicrob. Chemother.68(2),275–283 (2013).Crossref, Medline, CAS, Google Scholar101 Working group on new TB drugs. www.newtbdrugs.org/pipeline.phpGoogle Scholar102 Global alliance for TB. www.tballiance.org/pipeline/pipeline.phpGoogle Scholar103 Johnson and Johnson. Situro FDA advanced grant accelerated approval. www.investor.jnj.com/releaseDetail.cfm?ReleaseID=730893&year=2013Google Scholar104 Phase 2a EBA Trial of AZD5847. www.clinicaltrials.gov/ct2/show/NCT01516203Google ScholarFiguresReferencesRelatedDetailsCited ByInhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysisJournal of Biological Chemistry, Vol. 293, No. 44Perspective: Challenges and opportunities in TB drug discovery from phenotypic screeningBioorganic & Medicinal Chemistry, Vol. 23, No. 16 Vol. 5, No. 5 Follow us on social media for the latest updates Metrics Downloaded 70 times History Published online 10 April 2013 Published in print April 2013 Information© Future Science LtdKeywordsalternative approachcell-based approachtarget-based approachTB drug discoveryFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download